The arithmetic at Novo Nordisk is getting harder to follow. On one page of the ledger, the Danish drugmaker delivered a second-quarter performance that beat its own expectations, lifted its full-year guidance, and continued returning cash to shareholders. On the other page sit 6.3 billion Danish kroner in writedowns, a failed late-stage trial, and a share price that investors sold off by as much as 7.1 percent in Copenhagen on Thursday.
The market’s reaction was telling. The oral version of Wegovy — the pill form of the blockbuster weight-loss drug — generated 3.22 billion kroner in quarterly sales, marginally below the 3.27 billion kroner analysts had penciled in. Meeting the bar, it turns out, was no longer enough. Investors wanted a beat, and Novo Nordisk delivered only a confirmation.
The Two-Sided Numbers
Stripping out one-off items, revenue climbed 7 percent in the second quarter to 78.488 billion kroner on a currency-adjusted basis, while adjusted operating profit advanced 11 percent to 33.389 billion kroner. The company also narrowed its full-year outlook, now guiding for adjusted growth of between 0 and minus 6 percent — a meaningful improvement over the previous range of minus 4 to minus 12 percent.
The reported figures tell a less flattering story. Operating profit fell 19 percent to 25.9 billion kroner, dragged down by impairments on pipeline projects. Monlunabant, an obesity drug candidate, accounted for 4.0 billion kroner of the 6.3 billion kroner in writedowns. The gap between the adjusted and reported numbers is the gap between Novo Nordisk’s operational strength and its strategic vulnerability.
Adding to the pressure, the phase 3 ZEUS trial evaluating Ziltivekimab in cardiovascular disease missed its primary endpoint — a setback that received little attention in the initial coverage but matters for a company trying to diversify beyond weight management.
A Credibility Problem That Guidance Can’t Fix
The raised forecast should have been a moment of relief. It wasn’t. When investors ignore good news because they no longer trust management’s framing, that is a signal that runs deeper than any single metric.
CEO Maziar Mike Doustdar, who took the helm relatively recently, spent Wednesday trying to reassure investors, promising faster research and a rebuilt pipeline. The skepticism persists. Jefferies analysts noted on Thursday that “many open questions for 2027” remain regarding Novo Nordisk’s long-term competitiveness in the obesity market. Morningstar cut its fair value estimate to 285 kroner from 311 kroner, citing lower long-term gross margin assumptions and weaker expectations for CagriSema following the Reimagine-4 trial results.
The CagriSema disappointment is the wound that keeps reopening. The ZEUS-related writedowns and the July setback from the CagriSema data — which sent the US-listed shares down 8.8 percent — have left Novo Nordisk without a clear second growth pillar. The oral Wegovy tablet, approved by the European Commission in mid-July as the first oral GLP-1 treatment for weight reduction in Europe, is now expected to carry more of the load.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Structural Pressures and Defensive Wins
The company is also navigating a cost-cutting program announced in September 2025, which involves eliminating 11 percent of its workforce — roughly 9,000 positions, including 5,000 in Denmark. Nearly a year after its announcement, the restructuring remains a topic of investor debate, a sign that Novo Nordisk’s structural challenges resist a quick fix.
There are counterweights. The board declared an interim dividend of 3.75 kroner per share, with the ex-date set for August 14. The share buyback program, sized at 15 billion kroner, continues: between July 27 and August 3, the company repurchased 1.145 million B-shares at an average price of around 324 kroner. Through early August, roughly 27 million B-shares had been bought back for 7.53 billion kroner under the program. On Thursday, a court in The Hague also ruled in Novo Nordisk’s favor, temporarily barring Dutch pharmacy Ceban Ziekenhuisfarmacie from distributing a semaglutide nasal spray that the court found infringes the company’s protective certificate.
Political risk looms as well. The German government signaled earlier this week that it may reconsider the reimbursement status of “lifestyle medications” such as Ozempic and Wegovy — a development that could hit Novo Nordisk in a market segment already under scrutiny.
The Competitive Arithmetic
Eli Lilly, meanwhile, is widening its lead in injectable GLP-1 therapies. The US rival reported quarterly revenue above expectations on Wednesday and raised its full-year guidance to between 85 billion and 87 billion US dollars. For Novo Nordisk, the competitive gap is no longer hypothetical; it is quantified in each earnings cycle.
The share price reflects the tension. After closing last week at 38.72 euros, the stock has fallen 13.37 percent over seven days and sits nearly 30 percent below its 52-week high. It has recovered 30.86 percent from its yearly low of 30.25 euros, trading at 39.59 euros on Thursday with a gain of 2.25 percent. Still, the stock remains 1.76 percent below its 200-day moving average, and the relative strength index of 39.9 suggests sentiment has not convincingly turned.
What September Will Decide
The capital markets day scheduled for September 20 and 21 has become the focal point. Management is expected to revise its strategy and financial targets — an opportunity to articulate how it plans to fill the CagriSema-shaped hole in its growth narrative. The first nine months’ results on November 4 will then provide the hard evidence of whether the more optimistic guidance has substance.
Between now and then, the oral Wegovy rollout in Europe will be the metric to watch. If the tablet gains traction faster than expected, it could partially compensate for the missing second pillar. If sales again fall short of estimates, the recovery could stall and the stock may drift back toward its March lows.
The September meeting is not merely a calendar event. It is the moment when Novo Nordisk must demonstrate whether it can rebuild trust as quickly as it builds molecules. The raised guidance bought time; the capital markets day will determine whether that time is well spent.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from August 6 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 6.
Novo Nordisk: Buy or sell? Read more here...
